Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

23.49
+0.93004.12%
Post-market: 23.490.00000.00%16:10 EST
Volume:1.82M
Turnover:42.57M
Market Cap:2.97B
PE:65.59
High:23.58
Open:22.68
Low:22.57
Close:22.56
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:0.31
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:7.41
PE(LYR):-14.71

Loading ...

How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors

Simply Wall St.
·
Jan 31

Apellis Pharmaceuticals Initiated at Equal-Weight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on Apellis Pharmaceuticals With Equal Weight Rating, $24 Price Target

MT Newswires Live
·
Jan 28

S&P Dow Jones Indices: TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400

THOMSON REUTERS
·
Jan 28

Apellis CEO Cedric Francois Reports Sale of Common Shares

Reuters
·
Jan 24

Wedbush Lowers Price Target on Apellis Pharmaceuticals to $20 From $22, Keeps Neutral Rating

MT Newswires Live
·
Jan 23

Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares

Reuters
·
Jan 22

How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake

Simply Wall St.
·
Jan 22

Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says

MT Newswires Live
·
Jan 22

BofA Securities Upgrades Apellis Pharmaceuticals to Buy From Neutral, $28 Price Target

MT Newswires Live
·
Jan 21

Apellis Pharmaceuticals Shares Add 3.7% Premarket After Bofa Global Research Upgrades to Buy From Neutral

THOMSON REUTERS
·
Jan 21

Apellis Pharmaceuticals Inc : Bofa Global Research Raises to Buy From Neutral

THOMSON REUTERS
·
Jan 21

Apellis Pharmaceuticals Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Jan 21

Apellis upgraded to Buy from Neutral at BofA

TIPRANKS
·
Jan 21

U.S. RESEARCH ROUNDUP-IBM, KLA, WEX

Reuters
·
Jan 21

RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 20

Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases

MT Newswires Live
·
Jan 16

European Commission Approves Aspaveli by Sobi for Treatment of C3G and Primary IC-MPGN

Reuters
·
Jan 16

Apellis CEO Cedric Francois Reports Disposal of Common Shares

Reuters
·
Jan 16

Apellis Pharmaceuticals (APLS) Receives a Buy from Citi

TIPRANKS
·
Jan 15